

Posters P01 – P24

P-01 Patient experience of initiating unplanned hemodialysis

Eva -Lena Margareta Nilsson

Skanes University Hospital Malmö Sweden

P-02 Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy

Björn Peters¹

JoachimBeige², JustynaSiwyc³, MichaelRudnicki⁴, RalphWendt⁵, AlbertoOrtiz⁶, AnaBelen Sanz⁶, HaraldMischak³, Heather N.Reich⁷, SalmirNasic¹, DanaMahmood⁸, AndersPersson⁹, AndersFerntröm¹⁰, MariaWeiner¹⁰, BerndStegmayr¹¹

¹ Skaraborg Hospital Skövde Sweden

² Kuratorium for Dialysis and Transplantation Neu Isenburg/Leipzig Germany

³ Mosaiques diagnostics GmbH Hannover Germany

⁴ Medical University Innsbruck Innsbruck Austria

⁵ Hospital St. Georg Leipzig Germany

⁶ Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD UAM) Madrid Spain

⁷ University of Toronto and University Health Network, Toronto Toronto Canada

⁸ Umeå University Östersund Sweden

⁹ Umeå University Sundsvall Sweden

¹⁰ Linköping University Linköping Sweden

¹¹ Umeå University Umeå Sweden

P-03 Itch reduction with difelikefalin correlates with improved sleep quality in haemodialysis patients with pruritus

Daniel E. Weiner¹

ThiloSchauffer², SebastianWalpen², IsabelleMorin², WarrenWen³, SarbaniBhaduri⁴, FrédériqueMenzaghi³, Michael J.Germain⁵

¹ Tufts Medical Center Boston, MA United States

² CSL Vifor Glattbrugg Switzerland

³ Cara Therapeutics Stamford, CT United States

⁴ Bhadouri Biotech Consulting El Paso, TX United States

⁵ Baystate Medical Center Springfield, MA United States

P-04 The association between long troponin forms and mortality in CKD4-5 patients – The CADKID study.

Tapio Hellman¹

SelmaSalonen², RoosaLankinen¹, MarkusHakamäki¹, KajMetsärinne¹, K.E. JuhaniAiraksinen¹, Mikko J.Järvisalo³, SaaraWittfooth²

¹ Turku University Hospital Turku Finland

² University of Turku Turku Finland

³ Kanta-Häme Central Hospital Hämeenlinna Finland

P-05 Proteinuria reduction with sparsentan in immunoglobulin A nephropathy (IgAN): PROTECT study interim results

Jai Radhakrishnan ¹

Muh GeotWong ², Hiddo JLHeerspink ³, JensNilsson ⁴, RadkoKomers ⁵, AlexMercer ⁶, VladoPerkovic ⁷

¹ Columbia University Medical Center New York United States

² Concord Repatriation General Hospital Australia

³ University of Groningen Netherlands

⁴ CSL Vifor Sweden

⁵ Travere Therapeutics, Inc. United States

⁶ JAMCO Pharma Consulting Sweden

⁷ University of New South Wales Australia

P-06 Less microbubbles entered the patients using the venous chamber Emboless® during haemodialysis.

Ulf, Forsberg

BerndStegmayr, PerJonsson

Umea University Umea Sweden

P-07 Effects of exercise training on bone mineral density in different stages of chronic kidney disease: a substudy of RENEXC-a randomized controlled trial

Vaida Petrauskiene ¹

Matthias Hellberg ², Philippa Svensson ², Yunan Zhou ², Naomi Clyne ²

¹ Department of Nephrology, Clinical Sciences Lund, Faculty of Medicine, Lund Univ Lund Sweden

² Department of Nephrology, Clinical Sciences Lund, Faculty of Medicine, Lund Univ Sweden

P-08 Impact of Concurring Major Complications on the Association of Acute Kidney Injury and Outcomes following Coronary Artery Bypass Surgery

Leon Arnar Heitmann ¹, Dadi Helgason ³

NannaSveinsdottir ¹, Solveig Helgadottir ², Olafur SkuliIndridason ², TomasGudbjartsson ²

¹ University of Iceland Reykjavik Iceland

² Landspítali University Hospital Reykjavik Iceland

³ Lund University Hospital Lund Sweden

P-09 Safety of difelikefalin in haemodialysis patients with moderate-to-severe CKD-associated pruritus

Kieran McCafferty ¹

ThiloSchauffer ², DespinaRuessmann ², WarrenWen ³, FrédériqueMenzaghi ³, StevenFishbane ⁴

¹ Barts Health NHS Trust London United Kingdom

² CSL Vifor Glattbrugg Switzerland

³ Cara Therapeutics Stamford, CT United States

⁴ Hofstra–Northwell University Great Neck, NY United States

P-10 Difelikefalin a cost-effective novel drug for Finnish adult patients on hemodialysis with chronic kidney disease-associated pruritus

Saku Väätäinen ², Kaj Metsärinne ⁴

Dana Enkusson ¹, ErkkiSoini ³

¹ CSL Vifor Solna Sweden

² ESIOR Oy, Kuopio, Finland Kuopio Finland

³ ESIOR Ltd. Kuopio Finland

⁴ Turku University Hospital Turku Finland

P-11 Pre-donation renal function, age, and body composition impact post-donation renal function

Eva Carlsson ¹

MarkusGäbel ², NiclasKvarnström ², Maria KSvensson ³

¹ Department of Medical Sciences Renal Medicine, Uppsala University, Uppsala Sweden

² The Transplant Centre, Sahlgrenska University Hospital Gothenburg Sweden

³ Department of Medical Sciences Renal Medicine, Uppsala University Uppsala Sweden

P-12 Influence of pregnancy and other clinical factors on post-donation kidney function in young women

Eva Carlsson ¹

HenrikOldgren ², AmirSedigh ³, Maria KSvensson ²

¹ Department of Medical Sciences Renal Medicine, Uppsala University, Uppsala Sweden

² Department of Medical Sciences Renal Medicine, Uppsala University Uppsala Sweden

³ Department of Surgical Sciences, Transplantation Surgery, Uppsala University Uppsala Sweden

P-13 All-Cause and Cause-Specific Mortality In ANCA-Associated Vasculitis: a Population-based Study

Anna Julia Wilding ¹

MariaWeiner ², JensRathmann ¹, MårtenSegelmark ¹, AladdinMohammad ¹

¹ Lund University Lund Sweden

² Linköping University Sweden

P-14 Marine n-3 PUFA and bone mineral density in patients with end stage renal disease

Bahram Hashemi Dam ¹

My Hanna SofiaSvensson ¹, SimonWinther ², MortenBøttcher ², Per Ramløvlv Larsen ³, Hanne SkouJørgensen ³

¹ Aalborg University Hospital Aalborg Denmark

² Gødstrup Hospital Herning Denmark

³ Aarhus University Hospital Aarhus Denmark

P-15 Complement Activation after Treatment with Imlifidase

Linnéa Sandström Tyrberg¹

ThomasHellmark¹, AnnaBlom², MårtenSegelmark¹

¹ Division of Nephrology, Department of Clinical Sciences in Lund, Lund University Lund Sweden

² Division of Protein Science Department of Translational Medicine Lund University Malmö Sweden

P-16 The impact of changes in numbers of glomerular macrophages between two consecutive biopsies on renal transplant graft survival

Salmir Nasic¹

Marie Eriksson², JohanMölne³, BerndStegmayr², ElisabethKenne Sarenmalm⁴, HenriAfgahi¹, BjörnPeters¹

¹ Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden

² Umeå University Umeå Sweden

³ University of Gothenburg Gothenburg Sweden

⁴ Skaraborg hospital Skövde Sweden

P-17 Rare case: tumoral calcinosis showing intensive 18FDG-activity in a patient on peritoneal dialysis

Jan Schipper¹

MichaelHinz², SebastianKoball², SteffenMitzner²

¹ Helios Kliniken Schwerin Schwerin Germany

² Universitätsmedizin Rostock Rostock Germany

P-18 Proteomic cardiovascular biomarkers and their relation to chronic kidney disease

Barbara Salzinger¹

KristinaLundwall¹, MarieEvans², JosefinMörtberg³, HåkanWallen¹, TomasJernberg¹, ThomasKahan¹, Pia Lundman¹, Per Tornvall⁴, DavidErlinge⁵, BertilLindahl⁶, JonasSpaak¹, StefanJacobson¹

¹ Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet Stockholm Sweden

² Department of Clinical Intervention and Technology, Karolinska Institutet Sweden

³ Department of Internal Medicine, Centre for Clinical Research Uppsala Sweden

⁴ Department of Clinical Science and Education, Södersjukhuset, Karolinska Sweden

⁵ Department of Cardiology, Clinical Sciences, Lund University Sweden

⁶ Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center Sweden

P-19 Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program

Camilla Tøndel¹

David GWarnock², OzlemGoker-Alpan³, John ABernat⁴, NicolaLongo⁵, AlešLinhart⁶, StephenWaldek⁷, SariAlon⁸, RaulChertkoff⁸, RossanaRocco⁹, Irene Koulinska¹⁰, AnatSakov¹¹, Eric LWallace²

¹ Haukeland University Hospital, Renal Research Group Bergen Norway

² The University of Alabama at Birmingham United States

- ³ Lysosomal and Rare Disorders Research and Treatment Center, Inc Fairfax United States
⁴ University of Iowa Hospitals and Clinics United States
⁵ University of Utah, Center for Clinical Translational Sciences Salt Lake City United States
⁶ Charles University and General University Hospital in Prague Prague Czech Republic
⁷ University of Sunderland Sunderland United Kingdom
⁸ Protalix Biotherapeutics Carmiel Israel
⁹ Chiesi Farmaceutici S.p.A Parma Italy
¹⁰ Chiesi USA Inc. Boston United States
¹¹ DataSights Haifa Israel

P-20 Incidence, prevalence and characteristics of patients with chronic kidney disease in primary care in Finland

Kaj Metsärinne¹

SaaraKajjala², BettinaMannerström¹, Line ElmerdahlFrederiksen³, SatuBrinkmann⁴

- ¹ Department of Medicine, Turku University Hospital Turku Finland
² Medaffcon Oy Espoo Finland
³ Cardiovascular, Renal and Metabolism, Medical Department, AstraZeneca Copenhagen Denmark
⁴ Heinola Health Center Heinola Finland

P-21 Long-term outcomes of CKD patients with Lupus Nephritis as compared to other etiologies: a nationwide cohort study

Charikleia Chrysostomou

FauconAnne-Laure, PeterBarany, MarieEvans

Karolinska Institutet Stockholm Sweden

P-22 Detection of renal fibrosis and prediction of kidney function decline: the role of kidney MRI and markers of accelerated renal ageing

Christian Aalborg¹

My Hanna SofiaSvensson², Jens DamJensen³, AnneNegård¹, SteffenRinggaard³

- ¹ Akershus University Hospital Lørenskog Norway
² Aalborg University Hospital Aalborg Denmark
³ Aarhus University Hospital Aarhus Denmark

P-23 Norwegian Kidney Biopsy Biobank

Stein Hallan

St Olav Hospital Trondheim Norway

P-24 Change in Albuminuria in Patients with ANCA-Associated Vasculitis (AAV) Treated with Avacopan

Annette Bruchfeld

Karolinska Institutet, Linköping University

Duvuru Geetha ¹ Frank B.Cortazar ², Alexandre Karras ³, HuibinYue ⁴, Peter A.Merkel ⁵, David R.W.Jayne ⁶,

¹ Johns Hopkins University Baltimore, MD United States

² Saint Peter's Hospital-Albany Albany, NY United States

³ University of Paris Cité, Paris United States

⁴ Amgen Inc. Thousand Oaks, CA United States

⁵ University of Pennsylvania Philadelphia, PA United States

⁶ University of Cambridge Cambridge United Kingdom